- Home
- TME vs JAZZ Comparison
TME vs JAZZ Comparison
Compare TME & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TME | JAZZ |
|---|---|---|
| Founded | N/A | 2003 |
| Country | China | Ireland |
| Employees | 5690 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 15.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | TME | JAZZ |
|---|---|---|
| Price | $8.38 | $230.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $19.44 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 11.2M | 872.7K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $10.73 | $6.22 |
| Revenue Next Year | $10.19 | $7.68 |
| P/E Ratio | ★ $15.69 | $51.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.04 | $105.00 |
| 52 Week High | $26.70 | $243.32 |
Technical Indicators
Market Signals| Indicator | TME | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 52.02 |
| Support Level | N/A | $222.49 |
| Resistance Level | $9.80 | $242.66 |
| Average True Range (ATR) | 0.28 | 6.56 |
| MACD | -0.08 | -1.07 |
| Stochastic Oscillator | 25.17 | 47.72 |
Price Performance
Historical ComparisonAbout TME Tencent Music Entertainment Group each representing two
Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.